Advisory Committee Asked To Look Beyond Primary Endpoint Outcomes In Zavesca Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is particularly interested whether the advisory committee takes into account the totality of data on Actelion's orphan drug Zavesca in considering its approvability.